GB2582361A - Adenosine receptor agonists - Google Patents

Adenosine receptor agonists Download PDF

Info

Publication number
GB2582361A
GB2582361A GB1903900.7A GB201903900A GB2582361A GB 2582361 A GB2582361 A GB 2582361A GB 201903900 A GB201903900 A GB 201903900A GB 2582361 A GB2582361 A GB 2582361A
Authority
GB
United Kingdom
Prior art keywords
compound
group
pain
bnocpa
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1903900.7A
Other languages
English (en)
Other versions
GB201903900D0 (en
Inventor
Frenguelli Bruno
Wall Mark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Warwick
Original Assignee
University of Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Warwick filed Critical University of Warwick
Priority to GB1903900.7A priority Critical patent/GB2582361A/en
Publication of GB201903900D0 publication Critical patent/GB201903900D0/en
Priority to EP20715187.9A priority patent/EP3941482A1/en
Priority to JP2022504738A priority patent/JP2022525706A/ja
Priority to PCT/GB2020/050734 priority patent/WO2020188288A1/en
Priority to US17/441,257 priority patent/US20220152077A1/en
Publication of GB2582361A publication Critical patent/GB2582361A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
GB1903900.7A 2019-03-21 2019-03-21 Adenosine receptor agonists Withdrawn GB2582361A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB1903900.7A GB2582361A (en) 2019-03-21 2019-03-21 Adenosine receptor agonists
EP20715187.9A EP3941482A1 (en) 2019-03-21 2020-03-19 Adenosine receptor agonists
JP2022504738A JP2022525706A (ja) 2019-03-21 2020-03-19 アデノシン受容体アゴニスト
PCT/GB2020/050734 WO2020188288A1 (en) 2019-03-21 2020-03-19 Adenosine receptor agonists
US17/441,257 US20220152077A1 (en) 2019-03-21 2020-03-19 Adenosine receptor agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1903900.7A GB2582361A (en) 2019-03-21 2019-03-21 Adenosine receptor agonists

Publications (2)

Publication Number Publication Date
GB201903900D0 GB201903900D0 (en) 2019-05-08
GB2582361A true GB2582361A (en) 2020-09-23

Family

ID=66381433

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1903900.7A Withdrawn GB2582361A (en) 2019-03-21 2019-03-21 Adenosine receptor agonists

Country Status (5)

Country Link
US (1) US20220152077A1 (enExample)
EP (1) EP3941482A1 (enExample)
JP (1) JP2022525706A (enExample)
GB (1) GB2582361A (enExample)
WO (1) WO2020188288A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113082020A (zh) * 2021-04-08 2021-07-09 徐州医科大学 一种腺苷受体激动剂的增强剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023418A1 (en) * 1992-05-14 1993-11-25 Novo Nordisk A/S Purine derivatives
WO2011119919A1 (en) * 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Adenosine compounds and their use thereof
WO2017137528A1 (en) * 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930075D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB9930085D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
ME01072B (me) * 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu
WO2011011919A1 (zh) * 2009-07-31 2011-02-03 新道生技股份有限公司 一种降血糖的组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023418A1 (en) * 1992-05-14 1993-11-25 Novo Nordisk A/S Purine derivatives
WO2011119919A1 (en) * 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Adenosine compounds and their use thereof
WO2017137528A1 (en) * 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Brain: A Journal of Neurology, vol. 125, no. 6, 2002, pages 1392-1401; Available from https://academic.oup.com/brain/article/125/6/1392/290423 *
British Journal of Pharmacology, vol. 129, no. Proceedings Supplement, 2000, page 76P; Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1910494/?page=38 *

Also Published As

Publication number Publication date
EP3941482A1 (en) 2022-01-26
US20220152077A1 (en) 2022-05-19
GB201903900D0 (en) 2019-05-08
WO2020188288A1 (en) 2020-09-24
JP2022525706A (ja) 2022-05-18

Similar Documents

Publication Publication Date Title
CA2264155C (en) N6 heterocyclic substituted adenosine derivatives
JP4366186B2 (ja) アデノシンＡ２ａ受容体のリガンドとして有用なトリアゾリル−イミダゾピリジンおよびトリアゾリルプリンの誘導体およびその薬物としての使用
JP5778663B2 (ja) ヒトの眼圧を低下させるための医薬組成物
JP2021169521A (ja) 痛覚過敏を治療する方法
JP2015528470A (ja) ブメタニド、フロセミド、およびピレタニドを含むループ利尿薬の類似体およびプロドラッグ、組成物、ならびに使用方法
KR20120055692A (ko) 화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드
JP2015501308A (ja) ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
TW200418460A (en) Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
RU2650682C2 (ru) Пирролзамещенное производное индолона, способ его получения, включающая его композиция и применение
JP2014514259A (ja) 疼痛および他の障害の処置のための化合物および方法
CA2839350A1 (en) The use of serotonin receptor agonists for treatment of movement disorders
TW201336500A (zh) 治療疼痛之方法及組合物
BRPI0619261A2 (pt) derivados de purina e métodos de uso desses
CN111518028A (zh) 一种一氧化氮供体型ripasudil衍生物及其制备方法和用途
AU2020201109A1 (en) NMDA receptor modulators and prodrugs, salts, and uses thereof
RU2576380C2 (ru) Фармацевтическая композиция для профилактики или лечения макулярной дегенерации
CN111253412A (zh) α-倒捻子素衍生物及其应用
CN109761958A (zh) 法舒地尔复合盐及其制备方法和用途
CA2369746A1 (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
NL8100808A (nl) 2-amino-3-hydroxy(fenyl)methylfenylazijnzuren, hun esters en amiden.
US20220152077A1 (en) Adenosine receptor agonists
MXPA05012797A (es) Uso de derivados de 2-amino-1,3-propanodiol para la preparacion de un medicamento para el tratamiento de varios tipos de dolor.
JP7228897B2 (ja) アダマンチルメチルアミン誘導体およびその医薬としての使用
JPWO2017131097A1 (ja) アダマンタン誘導体およびその使用
JP2018501219A (ja) 黄斑変性の予防、軽減または治療方法

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)